Shares of Qiagen NV (NASDAQ:QGEN) have received an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $28.25.

Several equities analysts recently weighed in on QGEN shares. TheStreet lowered shares of Qiagen NV from a “b-” rating to a “c” rating in a research report on Monday, April 24th. Zacks Investment Research lowered shares of Qiagen NV from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen NV in a research report on Tuesday, May 2nd. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen NV in a research report on Wednesday, May 3rd. Finally, Barclays PLC reiterated a “buy” rating and set a $33.00 target price on shares of Qiagen NV in a research report on Friday, May 5th.

Several institutional investors have recently added to or reduced their stakes in QGEN. Van ECK Associates Corp raised its position in Qiagen NV by 3.1% in the fourth quarter. Van ECK Associates Corp now owns 526,746 shares of the company’s stock worth $14,759,000 after buying an additional 15,918 shares during the period. State Street Corp raised its position in Qiagen NV by 4.4% in the fourth quarter. State Street Corp now owns 2,287,457 shares of the company’s stock worth $64,092,000 after buying an additional 95,778 shares during the period. Brown Capital Management LLC raised its position in Qiagen NV by 6.6% in the fourth quarter. Brown Capital Management LLC now owns 999,760 shares of the company’s stock worth $28,013,000 after buying an additional 61,539 shares during the period. Wetherby Asset Management Inc. raised its position in Qiagen NV by 4.2% in the fourth quarter. Wetherby Asset Management Inc. now owns 9,110 shares of the company’s stock worth $256,000 after buying an additional 367 shares during the period. Finally, Comerica Bank raised its position in Qiagen NV by 80.1% in the fourth quarter. Comerica Bank now owns 22,902 shares of the company’s stock worth $649,000 after buying an additional 10,186 shares during the period. Institutional investors own 60.68% of the company’s stock.

Shares of Qiagen NV (NASDAQ:QGEN) opened at 32.98 on Wednesday. Qiagen NV has a one year low of $20.71 and a one year high of $33.06. The company’s 50 day moving average is $30.85 and its 200 day moving average is $29.43. The company has a market cap of $7.51 billion, a P/E ratio of 91.61 and a beta of 1.05.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/31/qiagen-nv-qgen-receives-average-recommendation-of-hold-from-analysts.html.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.